Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer

Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients

NCT02683083 ·Status: COMPLETED ·Phase: PHASE1

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

NCT06198751 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast

NCT05267327 ·Status: NOT_YET_RECRUITING

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

NCT03671330 ·Status: COMPLETED ·Phase: PHASE2

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

NCT03839823 ·Status: COMPLETED ·Phase: PHASE2

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

NCT07129187 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

T-DM1 Combined With CDK4/6 Inhibitor Ribociclib

NCT06481956 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

NCT06795503 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

NCT03492918 ·Status: UNKNOWN ·Phase: PHASE2

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

NCT07180056 ·Status: RECRUITING

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190 ·Status: RECRUITING ·Phase: PHASE2

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

NCT00491816 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).

NCT05953909 ·Status: UNKNOWN

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

NCT01958021 ·Status: COMPLETED ·Phase: PHASE3

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

NCT03052634 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT06293898 ·Status: RECRUITING ·Phase: PHASE1

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

NCT02422615 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

NCT01525589 ·Status: COMPLETED ·Phase: PHASE2

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

NCT06587789 ·Status: RECRUITING

A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer

NCT03632941 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer

NCT03956654 ·Status: COMPLETED

An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.

NCT02657343 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.

NCT05263570 ·Status: RECRUITING